Dr. Lal Path Labs quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	798	670	+19.1%
EBITDA	248	192	+28.7%
EBITDA margin	31.0%	28.7%	+2.3 pts
Profit before tax	229	181	+26.3%
Net profit	171	134	+27.2%
EPS	₹10.15	₹15.88	−36.1%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	798	703	660	731	670	603	597	660	602	545	539	601	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	31.9	24.0	24.4	24.8	28.1	25.8	25.1	21.9	20.6	18.4	18.3	18.1
	830	727	684	755	698	628	622	682	623	564	557	619
	152	135	129	142	129	118	117	127	119	109	107	122
	133	129	135	132	132	115	126	124	117	105	109	105
	6.3	6.1	7.2	4.8	4.7	5.0	5.3	6.0	6.0	6.6	7.0	7.8
	44.4	44.6	42.1	40.5	34.6	36.4	35.5	35.3	34.7	36.6	36.0	35.9
	266	252	217	233	216	200	199	206	196	186	182	196
	601	567	530	552	517	475	484	499	473	444	441	467
	248	187	179	224	192	169	154	203	170	145	141	178
	203	142	137	184	158	133	119	167	135	108	105	142
Profit
	229	160	154	204	181	153	138	183	150	120	116	152
	0.0	0.0	−30.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	229	160	124	204	181	153	138	183	150	120	116	152
	59.7	27.4	39.5	47.3	45.0	39.3	39.5	48.4	44.8	32.6	34.4	43.1
	−1.5	0.5	−6.6	4.1	2.1	−41.4	0.7	3.9	−2.7	1.5	−0.7	−1.6
	58.2	27.9	32.9	51.4	47.1	−2.1	40.2	52.3	42.1	34.1	33.7	41.5
	171	132	91.4	152	134	156	98.1	131	108	85.8	82.2	111
	171	132	91.4	152	134	156	98.1	131	108	85.8	82.2	111
	1.4	4.3	0.3	1.5	−0.9	−2.6	−0.1	−0.8	−0.1	−0.9	0.2	−0.1
	172	137	91.7	154	133	153	98.0	130	108	84.9	82.4	111
	170	131	90.5	151	132	155	96.7	129	106	84.5	81.3	109
	1.0	0.9	0.9	1.6	1.6	0.7	1.4	1.6	1.4	1.3	0.9	1.4
Per share
	₹10.15	₹7.86	₹5.42	₹18.05	₹15.88	₹18.57	₹11.60	₹15.52	₹12.79	₹10.13	₹9.77	₹13.16
	₹10.13	₹7.85	₹5.41	₹18.01	₹15.85	₹18.54	₹11.58	₹15.48	₹12.76	₹10.12	₹9.76	₹13.12
Other comprehensive income — detail
	1.4	4.3	0.3	1.5	−0.9	−2.6	—	—	—	—	—	—
	1.7	5.7	0.4	1.8	−1.2	−3.6	0.1	−1.0	−0.2	−1.3	0.4	−0.2
	0.4	1.4	0.1	0.5	−0.3	−1.1	—	—	—	—	—	—
	—	—	—	—	—	—	0.1	−0.3	0.0	−0.3	0.1	−0.1
	0.1	0.0	0.0	0.2	—	−0.1	−0.1	−0.1	0.1	0.1	−0.1	0.0
	171	136	90.8	152	132	152	96.6	128	106	83.7	81.5	109
	1.0	0.9	0.9	1.6	1.6	0.7	1.4	1.6	1.4	1.2	0.9	1.4
Per share — as-filed variants
	₹10.15	₹7.86	₹5.42	₹18.05	₹15.88	₹18.57	₹11.60	₹15.52	₹12.79	₹10.13	₹9.77	₹13.16
	₹10.13	₹7.85	₹5.41	₹18.01	₹15.85	₹18.54	₹11.58	₹15.48	₹12.76	₹10.12	₹9.76	₹13.12
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	646	568	531	589	541	485	480	533	483	437	432	479
	81.0%	80.8%	80.5%	80.6%	80.8%	80.5%	80.4%	80.7%	80.2%	80.0%	80.1%	79.6%
Adjusted (ex-exceptional items) — derived
	229	160	154	204	181	153	138	183	150	120	116	152
	0.0	0.0	−30.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	171	132	114	152	134	156	98.1	131	108	85.8	82.2	111
	₹10.15	₹7.86	₹6.73	₹18.05	₹15.88	₹18.57	₹11.60	₹15.52	₹12.79	₹10.13	₹9.77	₹13.16

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LALPATHLAB₹1,911.70

Dr. Lal Path Labs Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersMETROPOLIS VIJAYA THYROCARE NATCOPHARM NEULANDLAB NH COHANCE SAILIFEMcap ₹32,040 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	601.3	538.9	545.4	601.9	660.2	596.7	602.6	669.8	730.6	659.8	702.7	797.7
Other Income	18.1	18.3	18.4	20.6	21.9	25.1	25.8	28.1	24.8	24.4	24.0	31.9
Total Income	619.4	557.2	563.8	622.5	682.1	621.8	628.4	697.9	755.4	684.2	726.7	829.6
Expenses
+ Cost of Materials Consumed	122.4	107.0	108.9	119.4	127.3	117.0	117.8	128.9	141.8	128.7	135.2	151.7
+ Employee Benefit Expense	105.4	109.0	105.4	116.6	124.0	126.4	115.4	132.3	132.2	134.5	128.8	132.7
+ Finance Costs	7.8	7.0	6.6	6.0	6.0	5.3	5.0	4.7	4.8	7.2	6.1	6.3
+ Depreciation & Amortisation	35.9	36.0	36.6	34.7	35.3	35.5	36.4	34.6	40.5	42.1	44.6	44.4
+ Other Expenses	195.7	182.3	186.4	195.9	206.4	199.3	200.4	216.3	232.5	217.3	251.9	265.8
Total Expenses	467.2	441.3	443.9	472.6	499.0	483.5	475.0	516.8	551.8	529.8	566.6	600.9
EBITDA	177.8	140.6	144.7	170.0	202.5	154.0	169.0	192.3	224.1	179.3	186.8	247.5
EBIT	141.9	104.6	108.1	135.3	167.2	118.5	132.6	157.7	183.6	137.2	142.2	203.1
Profit
PBT before Exceptional Items	152.2	115.9	119.9	149.9	183.1	138.3	153.4	181.1	203.6	154.4	160.1	228.7
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-30.1	0.0	0.0
Pretax Income	152.2	115.9	119.9	149.9	183.1	138.3	153.4	181.1	203.6	124.3	160.1	228.7
+ Current Tax	43.1	34.4	32.6	44.8	48.4	39.5	39.3	45.0	47.3	39.5	27.4	59.7
+ Deferred Tax	-1.6	-0.7	1.5	-2.7	3.9	0.7	-41.4	2.1	4.1	-6.6	0.5	-1.5
Tax Expense	41.5	33.7	34.1	42.1	52.3	40.2	-2.1	47.1	51.4	32.9	27.9	58.2
Net Income	110.7	82.2	85.8	107.8	130.8	98.1	155.5	134.0	152.2	91.4	132.2	170.5
+ Net Income — Continuing Ops	110.7	82.2	85.8	107.8	130.8	98.1	155.5	134.0	152.2	91.4	132.2	170.5
+ Other Comprehensive Income	-0.1	0.2	-0.9	-0.1	-0.8	-0.1	-2.6	-0.9	1.5	0.3	4.3	1.4
Total Comprehensive Income	110.6	82.4	84.9	107.7	130.0	98.0	152.9	133.1	153.7	91.7	136.5	171.9
Net Income to Common	109.3	81.3	84.5	106.4	129.2	96.7	154.8	132.4	150.6	90.5	131.3	169.5
Minority Interest	1.4	0.9	1.3	1.4	1.6	1.4	0.7	1.6	1.6	0.9	0.9	1.0
Per Share
Basic EPS	13.16	9.77	10.13	12.79	15.52	11.60	18.57	15.88	18.05	5.42	7.86	10.15
Diluted EPS	13.12	9.76	10.12	12.76	15.48	11.58	18.54	15.85	18.01	5.41	7.85	10.13
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-2.6	-0.9	1.5	0.3	4.3	1.4
+ Items NOT to be Reclassified to P&L	-0.2	0.4	-1.3	-0.2	-1.0	0.1	-3.6	-1.2	1.8	0.4	5.7	1.7
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-1.1	-0.3	0.5	0.1	1.4	0.4
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	0.1	-0.3	0.0	-0.3	0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	0.0	-0.1	0.1	0.1	-0.1	-0.1	-0.1	—	0.2	0.0	0.0	0.1
Comprehensive Income — Owners of Parent	109.2	81.5	83.7	106.3	128.4	96.6	152.2	131.5	152.1	90.8	135.6	170.9
Comprehensive Income — Non-controlling Interests	1.4	0.9	1.2	1.4	1.6	1.4	0.7	1.6	1.6	0.9	0.9	1.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	13.16	9.77	10.13	12.79	15.52	11.60	18.57	15.88	18.05	5.42	7.86	10.15
Diluted EPS — Continuing Operations	13.12	9.76	10.12	12.76	15.48	11.58	18.54	15.85	18.01	5.41	7.85	10.13
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	478.9	431.9	436.5	482.5	532.9	479.7	484.8	540.9	588.8	531.1	567.5	646.0
Gross Margin %	79.64	80.14	80.03	80.16	80.72	80.39	80.45	80.76	80.59	80.49	80.76	80.98
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	152.2	115.9	119.9	149.9	183.1	138.3	153.4	181.1	203.6	154.4	160.1	228.7
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-30.1	0.0	0.0
Net Income Adj (tax-effected)	110.7	82.2	85.8	107.8	130.8	98.1	155.5	134.0	152.2	113.5	132.2	170.5
EPS Adj	13.16	9.77	10.13	12.79	15.52	11.60	18.57	15.88	18.05	6.73	7.86	10.15
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	83.5	83.5	83.5	83.5	83.6	83.6	83.6	83.8	83.8	167.6	167.6	167.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Dr. Lal Path Labs Q2 FY27 results date

Dr. Lal Path Labs (NSE: LALPATHLAB) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 25 September 2026, which also lists a dividend. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹170 crore, up 28.0% from ₹132 crore in Q1 FY26 and up 29.1% from ₹131 crore in Q4 FY26. Revenue from operations was ₹798 crore, up 19.1% year on year and up 13.5% from the previous quarter.

Board-meeting notice filed: 25 September 2026
Q2 FY26 results (a year earlier): 31 October 2025
Q1 FY27 results (the latest): 24 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 25 Sep
Q1 FY27 net profit: ₹170 Cr+28.0% vs Q1 FY26+29.1% vs Q4 FY26
Q1 FY27 revenue: ₹798 Cr+19.1% vs Q1 FY26+13.5% vs Q4 FY26
Q1 FY27 operating margin: 25.5%+1.9 pts vs Q1 FY26+5.2 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹151 CrRevenue ₹731 Cr
Q1 FY27 EPS (basic): ₹10.15

Questions

When will Dr. Lal Path Labs announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 25 September 2026). Last year it reported Q2 FY26 on 31 October 2025.

What will Dr. Lal Path Labs' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹151 crore and revenue from operations ₹731 crore. The latest quarter, Q1 FY27, had a net profit of ₹170 crore and revenue of ₹798 crore.

What were Dr. Lal Path Labs' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹170 crore, up 28.0% from ₹132 crore in Q1 FY26 and up 29.1% from ₹131 crore in Q4 FY26. Revenue from operations was ₹798 crore, up 19.1% year on year and up 13.5% from the previous quarter.

How has Dr. Lal Path Labs' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹151 crore in Q2 FY26, ₹90.5 crore in Q3 FY26, ₹131 crore in Q4 FY26 and ₹170 crore in Q1 FY27. That is ₹542 crore over the four quarters, up 5.6% from ₹513 crore in the four quarters before. Revenue from operations: ₹731 crore, ₹660 crore, ₹703 crore and ₹798 crore.

What was Dr. Lal Path Labs' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹505 crore in FY26 (April 2025–March 2026), up 3.6% from ₹487 crore in FY25. It was ₹358 crore in FY24 and ₹239 crore in FY23: up 111.3% over three years, 28.3% a year on average.

What was Dr. Lal Path Labs' revenue in FY26?

Revenue from operations was ₹2,763 crore in FY26 (April 2025–March 2026), up 12.2% from ₹2,461 crore in FY25. It was ₹2,227 crore in FY24 and ₹2,017 crore in FY23: up 37.0% over three years, 11.1% a year on average.

Where do these Dr. Lal Path Labs figures come from?

From Dr. Lal Path Labs' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.